ADHD

Explore how placebo effects vary across psychiatric disorders, revealing significant symptom improvements, especially in major depressive disorder and generalized anxiety disorder.

Learn more about facets of pediatric ADHD with Stacy Doumas, MD, MBA

Justin Kei, MD, discusses relation of sex differences, lifestyle, and hormones with ADHD

Discover the latest insights on ADHD diagnosis and treatment, including new DSM-5 criteria and effective therapeutic strategies for diverse patient needs.

Cingulate's CTx-1301 shows promising phase 3 results for ADHD, offering effective once-daily dosing and potential FDA approval by 2026.

Discover how best to approach ADHD assessments and utilize tools such as the Mentavi Diagnostic Evaluation, which can help improve patient care and reduce stigma.

A reproductive psychiatrist discusses the implications of recent FDA announcements on medication use during pregnancy, emphasizing the importance of mental health for mothers and babies.

Cingulate's CTx-1301, a novel ADHD treatment, gains FDA review, promising rapid relief and sustained efficacy for patients.

New research reveals women with ADHD are diagnosed 5 years later than men, highlighting the need for improved awareness and early intervention.

Discover how Mentavi Health's innovative ADHD assessment enhances diagnosis speed, accuracy, and patient engagement in mental health care.

A recent study reveals higher substance use disorder rates in individuals with ADHD, highlighting significant sex differences and the impact of comorbid psychiatric conditions.

Reproductive psychiatrist Sarah Oreck, MD, MS challenges the FDA's claims linking acetaminophen use in pregnancy to autism and ADHD, advocating for informed maternal care.

Combining cognitive behavioral therapy with medication enhances ADHD treatment in adults, showing significant benefits within 3 months.

Thomas Priolo, MD discusses strategies to manage back-to-school changes in child and adolescent psychiatric care.

Stay updated on key psychopharmacology developments, including new treatments for schizophrenia and breakthroughs in depression therapy.

Our August theme: the complexities of ADHD, including assessment, treatment options, and comorbidities. Share your insights!

Research reveals significant risks of neonatal complications linked to in utero valproic acid exposure, emphasizing the need for careful management during pregnancy.

Cingulate secures a $4.3 million FDA fee waiver for its innovative ADHD treatment, CTx-1301, enhancing patient care with extended efficacy.

Panelists discuss how a patient named Kerstin was diagnosed with attention-deficity/hyperactivity disorder (ADHD) later in life during college when she struggled with organization and scheduling beyond her known dyslexia, leading to successful treatment with various stimulant medications including participation in clinical trials.

Panelists discuss how stimulant and nonstimulant attention-deficity/hyperactivity disorder (ADHD) medications have different adverse effect profiles, with stimulants causing concerns such as misuse potential, cardiovascular effects, tics, and growth suppression.

The FDA has updated ADHD stimulant labels, highlighting weight loss risks in children under 6. Stephen Mateka, DO, shares his updated treatment strategies.

Panelists discuss how a 17-year-old patient’s challenges with inattention, anxiety, and executive dysfunction ahead of college highlight the importance of balancing pharmacologic and nonpharmacologic attention-deficity/hyperactivity disorder (ADHD) treatments. They address concerns about stimulant use and medication diversion.

Panelists discuss how treatment adherence in patients with attention-deficity/hyperactivity disorder (ADHD) is often impacted by forgetfulness and misconceptions and how using tools such as pill organizers can significantly improve consistency and outcomes.

Marc Potenza, PhD, MD, explores the impact of online social activity on ADHD symptoms in adolescents, revealing significant gender differences in brain development and attention.

Panelists discuss how viloxazine fits into both pediatric and adult attention-deficity/hyperactivity disorder (ADHD) treatment plans, especially as a nonstimulant option for patients with complex cases or concerns about stimulant adverse effects, while emphasizing flexible dosing and caregiver involvement.